← Leaderboards
Madhav V Dhodapkar
Rockefeller University
$18,788,265
Attributed
$24,299,110
Total exposure
20
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.7M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$34,482,645 · 21
By mechanism
R01$13,967,003 · 6
U54$11,701,549 · 4
R35$5,844,585 · 1
UG3$1,635,697 · 1
K23$446,929 · 1
P30$411,237 · 2
Top collaborators
- Richard A Flavell7 shared
- Ignacio E. Sanz7 shared
- Karl Leonard Insogna5 shared
- Markus Gabriel Manz5 shared
- Noah Wolcott Palm2 shared
- Suresh S Ramalingam1 shared
Most similar at Rockefeller University
Same institution · by research overlap
- Sarah Jane Schlesinger$8,614,481
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMultiple MyelomaCellsImmuneTumorImmune ResponseMediatingImmune SystemBiologyResponseT-LymphocyteNeoplastic CellInflammationInsightPlasma CellsNovel StrategiesGrowthDendritic CellsImmunityRegulationImmunologyAntigensIn VivoPrevent
Grant awards (73)
Targeting microbial triggers of gammopathy for immunoprevention$846,118
UG3 · FY2025 · CA · contact PI
Improving immune modulation for smoldering myeloma$655,380
R01 · FY2025 · CA · contact PI
Cancer Immunotherapy Research Program$258,891
P30 · FY2025 · CA · contact PI
Improving immune modulation for smoldering myeloma$32,666
R01 · FY2025 · CA · contact PI
Targeting microbial triggers of gammopathy for immunoprevention$789,579
UG3 · FY2024 · CA · contact PI
Administrative Supplement for Emory SeroNet "Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity"$622,147
U54 · FY2024 · CA
Project-004$88,878
U54 · FY2024 · CA
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity$88,878
U54 · FY2024 · CA · contact PI
Cancer Immunotherapy Research Program$55,733
P30 · FY2024 · CA · contact PI
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity$3,057,531
U54 · FY2023 · CA
Cancer Immunotherapy Research Program$54,381
P30 · FY2023 · CA · contact PI
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity$1,995,375
U54 · FY2022 · CA
HARNESSING HOST RESPONSE TO PREVENT MYELOMA$913,781
R35 · FY2022 · CA · contact PI
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity$545,091
U54 · FY2022 · CA
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity$359,168
U54 · FY2022 · CA · contact PI
Project-004$199,538
U54 · FY2022 · CA
Cancer Genetics and Epigenetics$42,232
P30 · FY2022 · CA · contact PI
HARNESSING HOST RESPONSE TO PREVENT MYELOMA$936,000
R35 · FY2021 · CA · contact PI
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity$3,963,391
U54 · FY2020 · CA
HARNESSING HOST RESPONSE TO PREVENT MYELOMA$936,000
R35 · FY2020 · CA · contact PI
Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity$781,552
U54 · FY2020 · CA · contact PI
HARNESSING HOST RESPONSE TO PREVENT MYELOMA$328,564
R35 · FY2019 · CA · contact PI
Emory Clinical Oncology Career Development Award K12 Program$54,000
K12 · FY2019 · CA
HARNESSING HOST RESPONSE TO PREVENT MYELOMA$936,000
R35 · FY2018 · CA · contact PI
Harnessing Host Response to Prevent Myeloma$1,005,000
R35 · FY2017 · CA · contact PI
Harnessing Host Response to Prevent Myeloma$789,240
R35 · FY2016 · CA · contact PI
Anti-tumor Immunity in Myeloma$323,639
R01 · FY2016 · CA · contact PI
Targeting Thrombospondin 1 in Bone Resorption$374,625
R01 · FY2015 · AR
Anti-tumor Immunity in Myeloma$323,639
R01 · FY2015 · CA · contact PI
Understanding Hemotopoietic Neoplasias using Humanized Mice$966,410
R01 · FY2014 · CA
Targeting thrombospondin 1 in bone resorption$367,133
R01 · FY2014 · AR
Anti-tumor Immunity in Myeloma$313,930
R01 · FY2014 · CA · contact PI
Understanding Hemotopoietic Neoplasias using Humanized Mice$946,541
R01 · FY2013 · CA
Targeting thrombospondin 1 in bone resorption$355,716
R01 · FY2013 · AR
Anti-tumor Immunity in Myeloma$303,993
R01 · FY2013 · CA · contact PI
Immunity to stem cell antigens in preneoplastic gammopathy$268,604
R01 · FY2013 · CA · contact PI
Understanding Hemotopoietic Neoplasias using Humanized Mice$990,065
R01 · FY2012 · CA
Targeting thrombospondin 1 in bone resorption$373,313
R01 · FY2012 · AR
Anti-tumor Immunity in Myeloma$322,425
R01 · FY2012 · CA · contact PI
Immunity to stem cell antigens in preneoplastic gammopathy$238,051
R01 · FY2012 · CA · contact PI
Understanding Hemotopoietic Neoplasias using Humanized Mice$1,025,153
R01 · FY2011 · CA
Targeting thrombospondin 1 in bone resorption$372,375
R01 · FY2011 · AR
Blood Diseases$1
T32 · FY2011 · HL · contact PI
Immunity to stem cell antigens in preneoplastic gammopathy$1
R01 · FY2011 · CA · contact PI
Understanding Hemotopoietic Neoplasias using Humanized Mice$1,063,218
R01 · FY2010 · CA
Blood Diseases$360,748
T32 · FY2010 · HL · contact PI
Immunity to stem cell antigens in preneoplastic gammopathy$270,000
R01 · FY2010 · CA · contact PI
Targeting myeloma via dendritic cells$309,925
R01 · FY2009 · CA · contact PI
Immunity to stem cell antigens in preneoplastic gammopathy$270,000
R01 · FY2009 · CA · contact PI
Immunity to stem cell antigens in preneoplastic gammopathy$264,299
R01 · FY2009 · CA · contact PI
Anti-Tumor immunity in myeloma$321,696
R01 · FY2008 · CA · contact PI
Targeting myeloma via dendritic cells$309,925
R01 · FY2008 · CA · contact PI
Immunity to stem cell antigens in preneoplastic gammopathy$270,000
R01 · FY2008 · CA · contact PI
Anti-Tumor immunity in myeloma$328,499
R01 · FY2007 · CA · contact PI
Targeting myeloma via dendritic cells$316,480
R01 · FY2007 · CA · contact PI
Anti-Tumor immunity in myeloma$338,309
R01 · FY2006 · CA · contact PI
Targeting myeloma via dendritic cells$325,932
R01 · FY2006 · CA · contact PI
Anti-Tumor immunity in myeloma$346,108
R01 · FY2005 · CA
Targeting myeloma via dendritic cells$333,528
R01 · FY2005 · CA
DENDRITIC CELLS PULSED WITH ALPHA-GALACTOSYL CERAMIDE$30,084
M01 · FY2005 · RR
ANTI-TUMOR IMMUNITY IN MYELOMA$6,612
M01 · FY2005 · RR
Anti-Tumor immunity in myeloma$345,425
R01 · FY2004 · CA
Dendritic cells pulsed with alpha-galactosyl ceramide$13,003
M01 · FY2004 · RR
Anti-tumor immunity in myeloma$11,197
M01 · FY2004 · RR
EBV SPECIFIC THERAPY OF LYMPHOMA USING DENDRITIC CELLS$153,401
K23 · FY2002 · CA
Core--Immunology$0
P01 · FY2002 · CA
MATURATION STAGE AND ROUTE OF ADMINISTRATION ON IMMUNOGENICITY OF DENDRITIC CELLS$0
M01 · FY2002 · RR
EBV SPECIFIC THERAPY OF LYMPHOMA USING DENDRITIC CELLS$148,933
K23 · FY2001 · CA
Core--Immunology$0
P01 · FY2001 · CA
MATURATION STAGE AND ROUTE OF ADMINISTRATION ON IMMUNOGENICITY OF DENDRITIC CELLS$0
M01 · FY2001 · RR
EBV SPECIFIC THERAPY OF LYMPHOMA USING DENDRITIC CELLS$144,595
K23 · FY2000 · CA
Core--Immunology$0
P01 · FY2000 · CA
MATURATION STAGE ON IMMUNOGENICITY OF DENDRITIC CELLS$0
M01 · FY2000 · RR